Trial Profile
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 May 2020
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 26 May 2020 Results of Population Pharmacokinetic-Pharmacodynamic Relationships of Sarilumab from four phase I-III studies (NCT01011959, NCT01061736, NCT01709578, NCT01768572 ) published in the Clinical Pharmacokinetics
- 16 Nov 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01011959).
- 13 Nov 2009 Actual start date (December 2008), official title, actual patient number (60), location (USA), primary outcome, lead investigator (Radin A) and sanofi-aventis added as trial sponsor as reported by ClinicalTrials.gov.